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Abstract 
Here we assessed the effectiveness of cervical cancer screening using data from the 
Hiroshima Prefecture Cancer Registry regarding patient age at the start of screening 
and differences in screening intervals. A screening model was created to calculate the 
health status in relation to prognosis following cervical cancer screening and its 
influence on life expectancy. Epidemiological data on the mortality rate of cervical 
cancer by age groups and mortality rates from the Hiroshima Prefecture Cancer 
Registry were used for the model projections. Our results showed that life expectancy 
when screening rate was 100% compared with 0% was extended by approximately 1 
month. Furthermore, when the incidence of cervical cancer was 0% compared with the 
screening rate was 100%, life expectancy was extended by a maximum of 3 months. 
Moreover, among individuals affected by cervical cancer, a difference of 13 years in life 
expectancy was calculated between screened and unscreened groups. 
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Introduction 
In 2008, there were an estimated 530,000 new cervical cancer cases worldwide and 
about 270,000 deaths from the disease (The GLOBOCAN 2008 database - International 
Agency for Research on Cancer; http://www-dep.iarc.fr/; accessed on October 1, 2012). 
According to the Japanese cancer information service 
(http://ganjoho.jp/public/cancer/data/cervix_uteri.html; accessed on October 1, 2012; in 
Japanese), as of 2006, roughly 9000 women per year developed cervical cancer in Japan, 
of which approximately 2700 died from the disease. In recent years, there has been an 
increasing trend in both the incidence and mortality rate of cervical cancer in younger 
women in their 20s and peaking in those in their 30s. Furthermore, it was reported that 
invasive cervical cancer in the 20–29 year age group had increased 4-fold from 1984 to 
1996 (Urushigawa Kuni et al., 2001) and, 20 years from now, the number of cases is 
expected to increase by >1.5-fold. (Estimated cancer 5-year prevalence - Cancer 
Statistics 2007, p. 92–93, Cancer Research Foundation, Tokyo, Japan;  
http://ganjoho.jp/data/public/statistics/backnumber/odjrh3000000o8is-att/FIG21.PDF; 
accessed on October 1, 2012). It is believed that the increased incidence in cervical 
cancer is due to women having their first sexual experience at a younger age. 
The effectiveness of cervical cancer screening is widely recognized and while it 
is important to determine the rate of advanced cervical cancer cases, screening is also 
  4
important for early detection of the disease. However, the low rate of cervical cancer 
screening remains a crucial issue (Basic Plan to Promote Cancer Control). Although 
cervical cancer screening had been recommended annually, in 2004, the age to undergo 
an initial exam was lowered from 30 to 20 years and the interval between screenings 
was increased to 2 years. According to an international comparison of cancer mortality 
and screening rates, the rate of cervical cancer screening in Japan is extremely low 
compared with those in Europe and the USA (21% vs. 85%, respectively; International 
Comparisons of Cancer Mortality and Cancer Screening Rates; accessed on October 1, 
2012), which is believed to be a significant factor contributing to the delay in early 
detection. According to reports on cervical cancer screening, the most common reason 
why women do not undergo the procedure is that they do not have the time or it is too 
much of a trouble (48.3%) (http://www.cczeropro.jp/kenshin/img/result/result.pdf#search 
= “report on cervical cancer screening”; accessed on October 1, 2012). Although patients 
are exposed to virtually no risks or physical pain incurred by the scraping of cells from 
the cervix in itself, the psychological stress is considered significant (Guidelines for 
Cervical Cancer Screening Based on Effective Evaluation, 2009). Moreover, the 
disadvantages of cervical screening due to over-diagnosis and false-negative results 
should be considered (Guidelines for Cervical Cancer Screening Based on Effective 
Evaluation, 2009). 
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The Hiroshima Prefecture Cancer Registry was established in 2002 to collect 
data on residents of Hiroshima Prefecture who develop cancer from the time of 
diagnosis to recovery or until death and perform analyses according to cancers of 
different organs. The data is collected through a notification system, in which medical 
institutions within Hiroshima Prefecture submit data on every cancer patient at the 
time of diagnosis according to primary site, all cases of malignant tumors, including 
carcinomas in situ, and those with central nervous system tumors, regardless if they are 
benign or malignant. 
In 2007, there were 221 new cases of cervical cancer reported in Hiroshima Prefecture, 
while the number of deaths was 46 (Hiroshima Prefecture Cancer Registry, 2007), 
making it the 12th most common disease among women and the 15th leading cause of 
death. However, neither the incidence nor the mortality rates included carcinoma in 
situ cases. If we consider the age-adjusted incidence rate of cervical cancer in 2007, it 
tended to decrease in women aged >40 years, but increased in those 20–39 years old, 
thereby demonstrating the importance of early detection. Thus, if the rate of cervical 
screening is increased, it would allow for improved detection and treatment of early 
stage cervical cancer and uterus preservation by local excision. In other words, early 
detection is crucial to preserve fertility in young women and reduce the mortality rate of 
cervical cancer and subsequent medical care expenses. Therefore, we created a cancer 
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screening model based on data from the Hiroshima Prefecture Cancer Registry and 
quantitatively evaluated the extent of mean life expectancy according to rate of cervical 
cancer screening. 
 
Subjects and methods 
Here we evaluated invasive cervical cancer cases diagnosed between 2005 and 2007 and 
entered into the Hiroshima Prefecture Cancer Registry (Hiroshima Prefectural Medical 
Association, 2005; Hiroshima Prefectural Medical Association,2006 ; Hiroshima 
Prefectural Medical Association, 2007). Local cancer registry data includes the condition 
of cancer cases when first diagnosed and the extent of the lesion. Two groups were 
classified from these items, the screened group (n = 80) and the non-screened group (n = 
410). In the screened group, diagnosis was made by cancer screening, whereas in the 
non-screened group, cancer was diagnosed via “health/medical check-up,” “during 
observation for a different illness,” and “other or unknown.” 
 
Creation of a screening model 
 
Figure1. 
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In the present study, we created a screening model to estimate changes in life 
expectancy using Mathematica 8.0 computational software 
(http://www.wolfram.com/mathematica/new-in-8/), which included the incidence of 
cervical cancer (excluding carcinoma in situ) according to different age groups, death 
rate according to different age groups, death rate in 2009, age at initial examination or 
follow-up, cervical cancer screening rate within Hiroshima Prefecture, excess mortality 
rate of cervical cancer, age at first screening, and final age calculated from Hiroshima 
Prefecture Cancer Registry data. To evaluate changes in life expectancy according to 
changes in cervical cancer screening, the incidence and mortality rates of cervical 
cancer in Japan were estimated with the model and compared with epidemiological data 
from the Hiroshima Prefecture Cancer Registry and the validity of the estimation model 
was verified. Furthermore, changes in risk factors due to human papillomavirus (HPV) 
infection prevention were not included because there was insufficient evidence to 
determine whether HPV testing lowered the cervical cancer mortality rate. 
The screening model was designed to reflect changes in health status over time. At the 
time of the start of the simulation, all 100,000 virtual cohort members were healthy and 
over time (1 year) their health status was modified according to probable 
disease-specific changes, such as “cervical cancer localization” and “invasion of adjacent 
organs by cervical cancer.” Moreover, all virtual cohort members ended up “dying from 
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cervical cancer” or “dying from other causes” using a simulation including a maximum 
life span of 100 years. 
 
Values used in the screening model 
  
Table 1-1.  
 
For clinical cervical cancer staging, we used the Union for International Cancer Control 
Tumor-Lymph node-Metastasis classification system and other cancer staging manuals 
developed by various academic societies and research institutions, while the local 
cancer registry was used to determine the extent of lesions modified into four stages: (1) 
localized; (2) regional lymph node metastasis; (3) invasion of adjacent organs; and (4) 
distal metastasis. In the model, “extent of lesion” was designated as a stage and the 
parameter value was estimated so that the likelihood was maximized from observed 
data using the maximum likelihood method. Cervical cancer screening reduces the 
incidence of invasive cancer by early detection and treatment of precancerous lesions 
and carcinomas in situ, and is expected to reduce the cervical cancer mortality rate.  
However, when suitable treatment is administered, even in cases with precancerous 
lesions or carcinoma in situ, the tumor control rate of carcinoma in situ (stage 0) is 
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reportedly almost 100% (Quinn MA et al.,2006). In other words, there was not much 
difference between healthy individuals and the death rate. Moreover, it is rare to 
progress to advanced stage cancer; thus, we excluded carcinoma in situ from the 
screening model. 
 
Other parameters 
 
Table 1-2.  
 
Numerical values of the incidence and mortality rates of cervical cancer according to 
different age groups were obtained from the Hiroshima Prefecture Cancer Registry 
(2005–2007). For the overall mortality rate, we included the mortality rates of other 
diseases as analytical parameters obtained from the Abridged Life Table of National 
Health Trends (2010–2011). Screening age was assumed as 20–65 years, 30–65 years, 
and 40–65 years. Intervals between screenings were defined from 1 to 5 years. 
According to data obtained from reports on community health services and promotion, 
the cervical cancer screening rate was 20%. Regression analysis was performed to 
determine a coefficient for the excess mortality rate of cervical cancer from the survival 
curve of the 5-year survival rate. The age at start of follow-up was set at 20 years to 
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study the effect of screening. 
 
Evaluation of mean life expectancy 
The mean life expectancy under each screening condition was evaluated based on the 
maximum theoretical value of the effects of cervical cancer screening (life expectancy 
from the mortality rate of all causes of death when the incidence rate of cervical cancer 
is 0% minus the life expectancy when the cervical cancer screening rate is 0%). 
 
Mean life expectancy of cervical cancer patients 
We calculated the difference in life expectancy between the screened group and the 
non-screened group among cervical cancer patients.  
 
3. Results 
 
Model validity 
Model validity was verified by comparing estimated values calculated by the screening 
model against the epidemiological data calculated from the Hiroshima Prefecture 
Cancer Registry (incidence and mortality rates of cervical cancer). According to our 
model, the expected incidence rate of cervical cancer was 15.3 cases/100,000 women, 
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whereas the Hiroshima Prefecture database reported an incidence rate of 17.18 
cases/100,000 women, thereby confirming the validity of the model (Figure 2-1).  
Furthermore, we confirmed the estimated mortality rate calculated using the model as 
6.9 deaths/100,000 women (Figure 2-2). 
 
Figure2-1. 
Figure2-2. 
 
Estimated mea life expectancy of cervical cancer patients 
 
Table2 
 
Based on the results of a simulation with a virtual static population of 100,000 cases 
with a cervical cancer incidence rate of 0%, the mean life expectancy of women was 
87.523 years, but when the cervical cancer screening rate was 100%, the maximum life 
expectancy was 87.382 years. Furthermore, the mean life expectancy of women with a 
history of cervical cancer, but with a screening rate of 0%, was calculated to be 87.309 
years. The theoretical maximum value of cervical cancer screening was 78 days (0.21 
years; range, 87.523–87.309 years). Moreover, the mean life expectancy with a screening 
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rate of 100%, compared with a screening rate of 0%, was increased by 26 days (0.07 
years; range, 87.382–87.309 years). 
 
Age at first screening 
Figure3. 
 
The age at the start of cervical cancer screening and the interval between screenings of 
the 100,000 virtual cohort members were adjusted to compare the efficacy of screening 
(screening rate, 100%). When the age at the start of screening (screening interval, 1 
year; screening rate, 100%) was 20 years, the screening efficacy was approximately 34%, 
at 30 years, it was 32%, and at 40 years, approximately 24% (Figure 3, Table 2). 
 
Mean life expectancy of cervical patients 
 
Figure4. 
 
As mentioned above, the theoretical maximum value of mass screening was 0.21 years; 
therefore, we calculated the difference in life expectancy between the screened group 
and the non-screened group among cervical cancer patients. For instance, if an 
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individual developed cervical cancer by age of 20, then there was a difference in mean 
life expectancy of approximately 13 years between the screened and non-screened 
groups (Figure 4). 
 
Discussion 
We examined the extent of changes in mean life expectancy according to changes in the 
rate of cervical cancer screening using a mathematical screening model. As a general 
rule, in Japan, women aged ≥30 years underwent annual screenings from 1983 to 2002. 
According to earlier studies and systems implemented in other nations (Sawaya GF et 
al., 2003; Sasieni P et al., 2003), as of 2003, women aged ≥20 years underwent 
screenings at 2-year intervals. While the age at the first screening was relatively young 
(20 years), a final age has not yet been established. Although a 2-year interval between 
screenings is short compared with other nations, the screening rate was very low. The 
current low rate of cervical cancer screenings may be attributed to the limited 
knowledge regarding preventive medicine and the correlation between HPV infection 
and cervical cancer in Japanese women, thus demonstrating that there is low interest in 
cancer screening (Vaccination Against Cervical Cancer,2008). Furthermore, cervical 
cancer is most common among women aged 20–40 years; thus, if we consider the fact 
that the employment rate in this age bracket is 65%–80%, then drastic reforms are 
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warranted, such as offering health examinations in the workplace or educating primary 
and junior high school students (Guidelines for Cervical Cancer Screening Based on 
Effective Evaluation, 2009). 
In the present screening model, when the cervical cancer screening rate was 100% 
(staring at 20 years of age at 1-year intervals) the mean life expectancy was calculated 
at 87.382 years and when the screening rate was 0%, the mean life expectancy 
decreased from 87.523 to 87.309 years, a difference of 0.21 years. Thus, if cervical 
cancer screening starts at 20 years of age, is performed at 2-year intervals, and the 
virtual cohort screening rate is 100%, we can expect a cervical cancer-free state close to 
approximately 30%, thereby indicating the extent to which cancer screening contributes 
to disease prevention. 
 
Figure5. 
The screening model also indicated that there was virtually no difference in the 
incidence of cervical cancer among women who began screening at 20 or 30 years of age, 
although there were more cervical cancer-free women among those who started 
screening at 20 years of age. 
Although the present screening model did not factor in carcinoma in situ, the incidence 
rate according to age group, including carcinoma in situ cases (diagnoses in 2007, 
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Figure 5), was 2.9% in young women aged 15–19 years, 14.7% of 20–24-year-olds, then 
suddenly increased to 63.9% in 25–29-year-olds, indicating the benefit of screening at 20 
years of age. If precancerous lesions and early stage cancers are detected and treated 
early, then the uterus can be preserved. Thus, to preserve fertility in young women, 
screening from 20 years of age is preferable. Although other nations recommend cervical 
cancer screening from 20 to 30 years of age, women aged ≥30 years in almost all 
countries are typically screened. In the United Kingdom, cervical cancer screening 
typically begins at the age of 25 years; however, in recent years, efforts have been made 
to begin screening at 20 years, but this recommendation remains controversial 
(National Health Service Cervical Screening Programme,2008). 
A comparison of the virtual cohort population at a 100% annual screening rate 
beginning at 30 years of age compared with 40 years revealed that the effects of 
screening decreased from 18% to 13%. The incidence rate of cervical cancer in 
Hiroshima (2007) was 15.5% in 30–34-year-olds, 34.9% in 35–39-year-olds, and 28.8% in 
40–44-year-olds. These results indicate the importance of cervical cancer screening 
before 30 years of age before the incidence rate peaks. 
Usually, cervical cancer screening is performed annually; however, in 2003, it was 
recommended for alternate years. In our screening model, a shorter interval between 
screenings increased the mean life expectancy. However, biennial screenings may be 
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problematic because women who consider screening may be unsure of the relevant year 
and thus may not undergo screening. Results of a case-control study conducted in Japan 
revealed that between individuals screened annually and biennially, there was a 
significant decrease in the rate of early detection in those who underwent biennial 
screenings (Morimura Y and Ito M, 2005). Moreover, a 2-year prevention may be 
anticipated from a negative biennial cytodiagnostic result; thus, annual screenings are 
likely much more effective (Sato S et al., 1997; Makino H et al., 1995). Therefore, an 
investigation into restoring annual screening is warranted. 
Recent analyses on cervical cancer have revealed the natural history of invasive cancer 
resulting from high-risk HPV infection of the cervical mucous membrane and the 
development of cervical carcinoma in situ or precancerous lesions (Cervical Cancer 
Screening Guidelines Based on Effective Evaluation,2009). In brief, there are 
approximately 150 types of HPV strains, of which 16 are high-risk (Miura S et al., 2006), 
and >90% of HPV infections are eliminated naturally, although persistent infections can 
lead to cancer. After the discovery of high-risk HPV infection, an HPV vaccine was 
developed to prevent the onset of cervical cancer and today it is administered 
extensively throughout the world. A cost-effectiveness analysis on the introduction of 
the HPV vaccine indicated that it may contribute to a decrease in cervical cancer 
mortality among young women, but was not effective in women aged ≥40 years; 
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therefore, screenings should be continued (Coupé VM ,et al ., 2009). Moreover, there is 
concern regarding the effect of HPV vaccination on cervical cancer screening. Although 
the HPV vaccine has been directly linked to cervical cancer prevention in young women, 
those already infected by the HPV virus realize no benefits from the vaccination. 
Furthermore, although the HPV vaccine prevents cervical cancer in 70% of cases 
(Muñoz N, et al .,2004 ; A National Clinical Guideline.2008), the remaining 30% of 
cervical cancer cases are not prevented. Therefore, as in the past, cervical cancer 
screening should be provided for women aged ≥30 years. 
The introduction of the HPV vaccine may greatly change the way cervical cancer 
screenings are performed in the future; however, since adolescents are the primary 
target for vaccine administration and there is no data regarding the duration HPV 
vaccine effectiveness, it is expected that preventive measures by cancer screening and 
vaccination will continue to coexist into the near future. HPV vaccine was not taken 
into account in this study, but screening procedures and preventive vaccines do exist for 
cervical cancer. Current cervical cancer treatments are designed to protect life and 
preserve the uterus, which is quite different compared with treatments for other solid 
cancers. Thus, in the future, cervical cancer therapy should also include preventative 
measures. 
The disadvantages of cervical cancer screening include false-negative and -positive 
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results as well as emotional stress and unnecessary medical costs incurred when 
detailed examinations are performed based on positive cases that are unwarranted 
(Cervical Cancer Screening Guidelines Based on Effective Evaluation,2009). In the 
virtual cohort population of 100,000 members, we calculated that when the screening 
rate was 20% and the screening interval was 1 year, there were a total of 4,499,868 
screenings, of which 449,864 (10%) resulted in false-positive diagnoses. Thus, the 
anxiety and psychological stress caused by false-positive cervical cancer results should 
be considered a disadvantage of screening; thus, a follow-up system needs to be included 
in the examinations. 
Nonetheless, early detection of cervical cancer allows for the preservation of the uterus 
and fertility. Moreover, the survival rate after treatment differs according to the tumor 
size and degree of invasion of cervical cancer when detected early. Therefore, early 
detection is crucial. As the rate of cervical screening increases, the incidence of cervical 
cancer will approach 0%. The cervical screening rate in Hiroshima Prefecture is below 
the national average and should, therefore, be increased. 
Epidemiological data used in this study was collected from the Hiroshima Prefecture 
Cancer Registry, a notification-based clinical registry, and, at present, the data can be 
expected to be highly accurate even at an international level, as epidemiological studies 
using this data have been shown to yield highly reliable results. Although cancer 
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registration is not mandatory in Japan, the nation is moving to make it so by the end of 
2013. Thus, if cancer registration becomes mandatory, we can expect highly accurate 
cancer registries to be established throughout Japan, which will allow us to ascertain 
trends that could not be estimated from regional data, clarify particularities of rare 
cancers, and analyze regional differences and survival rates. In the future, more data 
will be added to the registry thereby allowing further analyses. 
 
 
Conclusion 
We developed a cervical cancer screening model based on data from the Hiroshima 
Prefecture Cancer Registry. Here we examined the effect of mass cervical cancer 
screening on mean life expectancy, which, at most, increased by 1 month.  
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Legend 
Figure1. Transition probability 
µ： Mortality rate, δw： Mortality rate among those with cancer screening, δu：Mortality  
rate among those without cancer screening, se： Sensitivity, sp： Specificity, e： Cervical  
cancer screening rate 
Figure 2-1 Validity of incidence rate according to different age groups 
Figure 2-2 Validity of mortality rate according to different age groups 
Figure 3: Relative efficacy with a screening rate of 100% 
The age at the start of cervical cancer screening and the interval between screenings of 
the 100,000 virtual cohort members were adjusted to compare the efficacy of screening 
(screening rate, 100%). 
Figure 4. Mean life expectancy of cervical cancer patients 
The difference in life expectancy between the screened group and the non-screened 
group among cervical cancer patients. 
 
Table 1-1. Transition probability 
Transition probabilities used in the screening model.  
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Table 1-2. Constant values used in the model 
 
Additional parameters used in the screening model.  
Table2.  mean life expectancy according to condition and effects of screening 
Based on the results of a simulation with a virtual static population of 100,000 cases. 
Age at first screening of incidence rate is 100% 
*1: Localized 
*2: Adjacent organ invasion 
*3: Lymph node metastasis 
*4: Distal metastasis 
 
